A nurse is reinforcing education to a client who is prescribed clozapine. Which of the following findings should the nurse identify as consistent with agranulocytosis and instruct the client to monitor?

A. "Do you need any more resources or information?" This question focuses on offering additional resources rather than encouraging the client to explore their emotions. While it is useful for providing support, it does not promote self-reflection or invite the client to clarify their feelings. Therapeutic communication should aim to encourage deeper discussion rather than just addressing practical needs.
B. "Do you understand your next step in treatment?" Although this question ensures the client comprehends their treatment plan, it does not foster emotional expression or self-awareness. Understanding the next steps in care is important, but therapeutic communication should focus on exploring the client’s internal experiences rather than just confirming information. Encouraging open-ended reflection is more effective for clarifying emotions.
C. "You feel like you have the support needed to be successful." This statement encourages self-reflection and allows the client to clarify their feelings about their support system. It promotes therapeutic communication by inviting the client to assess their emotional needs and level of confidence. Open-ended statements like this help build trust and provide insight into the client’s concerns and perceptions.
D. "Tell me what kind of coping skills you have." While this question assesses the client's coping strategies, it does not directly facilitate emotional clarification. Asking about coping skills is useful for intervention planning, but it does not specifically address the client’s feelings. A more effective therapeutic approach would involve asking how the client feels about their ability to manage stress.

A. Fluoxetine. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used to treat depression, anxiety, and obsessive-compulsive disorder. It does not alleviate tardive dyskinesia symptoms and is not indicated for managing extrapyramidal side effects.
B. Diphenhydramine. Diphenhydramine is an antihistamine that can help with acute dystonic reactions due to its anticholinergic effects, but it does not treat tardive dyskinesia. Long-term use may even worsen movement disorders.
C. Naloxone. Naloxone is an opioid antagonist used to reverse opioid overdose. It has no effect on tardive dyskinesia, as this condition is related to prolonged dopamine receptor blockade rather than opioid activity.
D. Valbenazine. Valbenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor specifically approved for the treatment of tardive dyskinesia. It helps regulate dopamine release and reduces involuntary movements associated with the condition.